Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
The biggest killer after malaria - How to tackle RSV?

Respiratory syncytial virus (RSV) annually threatens many babies and there is currently no drug or vaccine to combat the disease. A lot of researc…


GlycoDelete: the road to plant-grown medicines

What if our pharmaceuticals could be grown in plants? It might sound like science fiction, but two VIB/UGent research groups are working hard to s…


Prof. Carmeliet as Chief Scientific Strategy Advisor at Oncurious

Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the ap…

POPULAR TAGS

Scientists isolate new antibodies to fight RSV

Written by DS on in the category news with the tags , , .


Researchers from VIB, UGent, the Geisel School of Medicine at Dartmouth and several collaborators developed a new antiviral strategy to fight human respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infections in children. The approach hinges on the use of single-domain antibodies, also known as Nanobodies®, which target and neutralize a vital protein in the virus, rendering it unable to enter lung cells. The research, published in the leading scientific journal Nature Communications, elucidates how these Nanobodies® interact with and neutralize the virus and demonstrates their ability to successfully protect mice from RSV infection and related inflammation.

RSV annually causes nearly 34 million illnesses in children under 5 years of age and can result in serious illness in both very young children and elderly people leading to hospitalization in up to 2% of cases. Despite intensive research and the virus’ status as a major pathogen, current methods of treatment rely almost exclusively on supportive care. With the goal of developing a new therapy to fight this disease, Xavier Saelens, professor at VIB-UGent, and his team developed Nanobodies® that target the protein that the virus needs to enter lung cells. The researchers showed that these Nanobodies® neutralized the virus in laboratory assays as well as in animals.

Producing RSV-targeting Nanobodies®

To obtain highly potent anti-viral molecules, the group of Saelens collaborated closely with Jason McLellan’s team from the Geisel School of Medicine, Darmouth College, and Barney Graham’s team from the National Institutes of Health in the USA to select, produce and purify Nanobodies® that specifically target the active but highly unstable form of the RSV fusion protein. Detailed structural analysis revealed that these Nanobodies® tightly bind to a very conserved pocket of the viral fusion protein, and that they provide anti-viral activity against many types of RSV.

Saelens: “We successfully developed molecules that act very potently against RSV, not only against multiple clinical isolates in cell culture, but also in animals. Our Nanobodies® are some of – if not the – most potent molecules ever isolated to fight RSV.”

McLellan: “Due to the small size of the Nanobodies®, these molecules can bind to a recessed cavity on the surface of the viral fusion protein and prevent this molecular machine from allowing the virus to enter lung cells.”

Development of a new therapy against RSV

There is no antiviral treatment available for patients (often infants) hospitalized with RSV. Therefore, there is high demand for an antiviral drug that can be applied therapeutically, i.e. after infection has occurred.

Iebe Rossey (VIB-UGent): “As a therapy, Nanobodies® are especially attractive because they are stable, soluble and can be administered rapidly and directly to the lung through inhalation. Rapid treatment with these Nanobodies® could potentially prevent or reduce RSV-related hospitalization, limiting great patient distress and reducing the costs of care.”

Moving from the lab to the clinic

The team’s next steps will revolve around transforming the Nanobodies® that they developed into a format that can be used in clinical tests.

Bert Schepens (VIB-UGent): “But we won’t be working toward this goal alone – our plan is to team up with an industrial partner to translate our findings into a therapeutic treatment that is useful for RSV patients.”

Reference

Saelens et al., Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state,  Nature Communications 2017
DOI: 10.1038/NCOMMS14158

RELATED ARTICLES
The biggest killer after malaria - How to tackle RSV?

Respiratory syncytial virus (RSV) annually threatens many babies and there is currently no drug or vaccine to combat the disease. A lot of researc…


GlycoDelete: the road to plant-grown medicines

What if our pharmaceuticals could be grown in plants? It might sound like science fiction, but two VIB/UGent research groups are working hard to s…


Prof. Carmeliet as Chief Scientific Strategy Advisor at Oncurious

Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the ap…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin V-Bio Ventures UGent Janssen Turnstone Flanders.bio KU Leuven XpandInnovation Itera Life Science GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.